Enterprise Europe Network

Experienced Maltese distribution and sales company in the medical / pharma products and devices sector, seeks partners under commercial agency and distribution agreements

Country of origin:
Country: 
MALTA
Opportunity:
External Id: 
BRMT20200825001
Published
25/08/2020
Last update
22/09/2020
Expiration date
23/09/2021

Keywords

Partner keyword: 
Human vaccines
Pharmaceutical Products / Drugs
Single Use Products and Consumer Goods
Diagnostic services
Surgical instrumentation and equipment
Drug delivery and other equipment
Laboratory equipment
Medical instruments
EXPRESS YOUR INTEREST

Summary

Summary: 
The Maltese company manages and distributes a vast portfolio of pharmaceuticals, medical consumables, generics, injectables and bio-similars. It is a leading company in the sector and is fully licensed by the Malta Medicines Authority. The company offers its established client networks, both national and international, to the right partner, either under a commercial agency or a distribution agreement.

Description

Description: 

The Maltese company opened its doors back in 2013 and is licensed by the Malta Medicines Authority. Their pharma business model is split into two: the main sector focuses on the private market where a team of trained sales professionals promote, market and sell medicinal products on a national level.
Their second section focuses on the national healthcare service where the company bids for government procurement contracts. The objective is always to deliver service excellence in both sectors which means high-level training of all personnel is ongoing.

The list of products required by the Malta national healthcare sector keeps growing year on year and so the company seeks to partner with reputable and trusted suppliers and remain in a position as a major candidate for government contracts.

In order to establish new business leads through trade intermediary cooperation agreements, the company is specifically looking for manufacturers of:
- Vaccines
- Finished medicinal formulations in forms of tablets and syrups
- Intravenal (IV) and intramuscular (IM) medicines
- Bio Similar medicine
- Food supplements as nutritional food drinks for the elderly
- Controlled Drug Medication

It is the company's intention to enter into commercial agency / distribution agreements with the manufacturers.

The company has the below licenses and offers its established client networks to the right partner:
- Wholesale Dealer Licence for Medicines (WDL)
- Licensed to handle Controlled Drugs
- Licensed in Goods Distribution Practice (GDP)
- Licensed in Goods Manufacturing Practice (GMP)

Since Malta falls under the European Union Legislation all medicinal products must be produced in EUGMP certified sites.

Advantages & innovations

Cooperation plus value: 
The Maltese company offers a holistic service and is in a position to support a potential partner with all aspects of the supply chain, including strategic consultancy which allows a pharmaceutical or medical devices company to develop a new customer base. Their newly built 1,600m2 warehouses are GDP [Good Distribution Practice] licensed and can accommodate narcotics, biologicals and cold-chain products. The company also has a GMP [Good Manufacturing Practice] license to be able to relabel products in-house. This company would be an appropriate partner for manufacturers that intend to expand their international markets.

Technical Specification or Expertise Sought

Cooperation sought: 
Manufacturers of: - Vaccines - Finished medicinal formulations in forms of tablets and syrups - Intravenal (IV) and intramuscular (IM) medicines - Bio Similar medicine - Food supplements as nutritional food drinks for the elderly - Controlled Drug Medication

Partner sought

Cooperation area: 
The company is interested in working with pharmaceutical and/or medical devices manufacturers who seek representation or assistance in targeting new markets. The company wishes to have a new brand of products to be able to bid for more government contracts. The partnership is envisaged under trade intermediary options.